Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05611450
Other study ID # 202100777B0
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 22, 2022
Est. completion date July 2024

Study information

Verified date November 2022
Source Chang Gung Memorial Hospital
Contact Kang Hua Chen, PhD
Phone +886-2118800
Email khc@mail.cgu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study's purpose is to understand the self-management needs of patients with NSCLC receiving targeted therapy, develop a disease self- management application (mHealth Application), and explore the effect of mHealth application on the self-efficacy and health status of patients receiving targeted therapy for NSCLC. This study adopts a two-group (pre-and-post-test) design experiment. This study is being conducted over a period of 3 years and is divided in two stages. This study enrolled patients with NSCLC in the outpatient clinic and ward of the Division of Chest Medicine in a northern medical center as the research participants. Stage 1 develop a disease self-management application and understands participants' needs by qualitative study. The participants are a purposive sample of 15-20 patients. Data discontinued when theme saturation is achieved. Stage 2 adopted convenient sampling to enroll 108 patients (54 in the experimental group and 54 in the control group) to evaluate the effectiveness of the disease self-management application. After participant's consent was obtained, this study performed the pre-test and randomized the participants. The experimental group received both routine care and the disease self-management App, while the control group received routine care and part of application. This study collected data before the patients received targeted therapy and in months 1, 3, 6, and 9 after treatment initiation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 108
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - ?20 years of age - diagnosed with advanced NSCLC - were epidermal growth factor, anaplastic lymphoma kinase...inhibitor-naive Exclusion Criteria: - had received other anti-cancer therapy - were difficulty with verbal expression or cognitive dysfunction

Study Design


Intervention

Other:
disease self-management application
The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire assessing participants' quality of life change from baseline at 1 month
Primary European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire assessing participants' quality of life change from baseline at 3 month
Primary European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire assessing participants' quality of life change from baseline at 6 month
Primary European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire assessing participants' quality of life change from baseline at 9 month
Primary NCI-CTCAE (ver 5.0) guideline assessing participants' skin toxicity grade change from baseline at 1 month
Primary NCI-CTCAE (ver 5.0) guideline assessing participants' skin toxicity grade change from baseline at 3 month
Primary NCI-CTCAE (ver 5.0) guideline assessing participants' skin toxicity grade change from baseline at 6 month
Primary NCI-CTCAE (ver 5.0) guideline assessing participants' skin toxicity grade change from baseline at 9 month
Secondary knowledge and skills with disease self-management questionnaire assessing participants' knowledge and skill ability with disease self-management change from baseline at 1 month
Secondary knowledge and skills with disease self-management questionnaire assessing participants' knowledge and skill ability with disease self-management change from baseline at 3 month
Secondary knowledge and skills with disease self-management questionnaire assessing participants' knowledge and skill ability with disease self-management change from baseline at 6 month
Secondary knowledge and skills with disease self-management questionnaire assessing participants' knowledge and skill ability with disease self-management change from baseline at 9 month
Secondary disease self-efficacy questionnaire assessing participants' self-efficacy with disease self-management change from baseline at 1 month
Secondary disease self-efficacy questionnaire assessing participants' self-efficacy with disease self-management change from baseline at 3 month
Secondary disease self-efficacy questionnaire assessing participants' self-efficacy with disease self-management change from baseline at 6 month
Secondary disease self-efficacy questionnaire assessing participants' self-efficacy with disease self-management change from baseline at 9 month
Secondary Hospital Anxiety and Depression Scale assessing participants' anxiety and depression change from baseline at 1 month
Secondary Hospital Anxiety and Depression Scale assessing participants' anxiety and depression change from baseline at 3 month
Secondary Hospital Anxiety and Depression Scale assessing participants' anxiety and depression change from baseline at 6 month
Secondary Hospital Anxiety and Depression Scale assessing participants' anxiety and depression change from baseline at 9 month
Secondary Medical Outcomes Study-Social Support Survey assessing participants' social support chang from baseline at 1 month
Secondary Medical Outcomes Study-Social Support Survey assessing participants' social support chang from baseline at 3 month
Secondary Medical Outcomes Study-Social Support Survey assessing participants' social support chang from baseline at 6 month
Secondary Medical Outcomes Study-Social Support Survey assessing participants' social support chang from baseline at 9 month
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1